-1.9 C
Munich
Friday, January 27, 2023

CeCors, Inc. (OTCMKTS: CEOS) Steady Rise Northbound After Co Acquires VetComm & Beefs Up its BOD and Management Team

CeCors, Inc. (OTCMKTS: CEOS) is making a big move northbound since making a major reversal off $0.011 lows rocketing up 44% on Monday on its biggest volume since early 2021 trading 14.8 million shares or about $4 million in dollar volume for the day. The move comes several days after CEOS announced it has signed a binding LOI to acquire VetComm Corp., a veteran’s education, and benefits company focused on assisting the over 20 million United States veterans that qualify for underutilized annual benefits and owed compensation. 

Many have pointed out that they like the direction that CEOS is going and it’s easy to see why; the Company has been busy behind the scenes bringing on a top-level management team and BOD appointed Dr. Shahiem Hartley as well as Renowned Biochemist Dr. Michael J. McCarthyto its Medical Advisory Board. They also appointed Corporate Executive & Scientific Innovator John Gustin as Head of Global Business Development. We will be updating on CEOS when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.  

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Veteran Testimonials - Veteran VA Disability Claim Services | VetComm.usVetcomm’s mission is to help Veterans get their disability compensation usually between $1,000 and $3,000 per month. The Company has an ambitious goal to help One Million Veterans get their disability compensation out of the 17 million Veterans currently living without it. The revenue potential for Vetcomm is VERY significant if they achieve anywhere near their goal as they charge between $997 one-time fee per Veteran or 12 payments of $97/month. 

PsyKey, Inc., Achieves Key Revenue Milestone With Purchase Order Of Its Functional Mushroom ProductsCeCors, Inc. (OTCMKTS: CEOS) operating through its subsidiary PsyKey Inc.,CEOS is in the business of research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations, for use in its premium quality functional product lines to help improve and optimize everyday life. PsyKey is also engaged in the scientific development of patentable technologies pertaining to the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the fast-evolving psychedelic market.  

During the first two quarters of 2022 the company successfully launched its first product offering, PsyKey Functional Mushroom Infused coffees. The coffee line launched in four unique formulations: Mind & Memory, Calm & Relaxed, Immune & Defend, and Reishi Gano Good. Since our initial launch, we have had tremendous feedback on the taste and efficacy of the product offering, which has resulted in the company receiving bulk purchase orders for our product, which should provide a substantial increase in revenue for PsyKey commencing Q3. The positive feedback on products marketed in our initial product offering has also resulted in the development of various new functional mushroom products the Company intends on introducing over the coming months. 

In line with the Company’s plans for rapid growth, management is actively pursuing revenue-generating acquisitions and strategic partnerships. The Company is also in the final stages, pending delivery of GAAP compliant financial statements, of closing our acquisition of Nutra-Rox LLC. The Nutra-Rox functional carbonated crystal delivery technology allows for bioavailable ingredients such as functional mushrooms, adaptogens, and nootropics to be delivered via “popping” carbonated crystals. Nutra-Rox is also the developer of Breath Rox®, a sugar-free popping fresh breath treatment which delivers zinc gluconate to help reduce odor-causing bacteria in the mouth. The Nutra-Rox management team has over 50 years of collective experience in research, product development, manufacturing, branding, marketing, sales, and distribution, which should allow CeCors to quickly capitalize on additional revenue generation across newly acquired product lines. 

To Find out the inside Scoop on CEOS Subscribe to newsytrends.com Right Now by entering your Email in the box below

CEOS

On December 19 CEOS announced it has signed a binding letter of intent (LOI) with VetComm Corp. VetComm is a veteran’s education, and benefits company focused on assisting the over 20 million United States veterans that qualify for underutilized annual benefits and owed compensation. As a result, billions of dollars in veteran benefits go unclaimed every month in the United States. Published author, entrepreneur, founder, and CEO of numerous diversified companies, United States Marine Corps (USMC) veteran Kate Monroe founded VetComm Corp. Kate has parlayed her marine corps experience into developing the premier veterans’ benefits company in the United States.  

Amar Bhatal, President of PsyKey, Inc. stated: “We are delighted to begin this journey with VetComm. The fact that they have over a quarter million veterans in their database with 2000 added every day really provides a great platform for both parties to benefit and to benefit veterans who need it the most.” 

Kate Monroe, Founder and Chief Executive Officer of VetComm Corp. stated: “I’m very excited to begin discussions with CeCors. I’m intrigued by the possibilities of integrating the PsyKey Live app into our platform and seeing how CeCors’ subsidiary PsyKey’s current and future mental wellness products can help veterans on our platform. Most veterans feel guilty for applying for benefits that are afforded to them. Veterans always put the love of country over anything. Unfortunately, that patriotism is costing them money they are entitled to for protecting and serving our great nation. At VetComm, we’re closing that gap through education and a platform that takes away the stress of applying for these entitled benefits and compensation. We continue to grow and hope for a very robust first quarter of 2023.” 

 We have something big coming Subscribe Right Now!

Currently trading at a $6.3 million market valuation CEOS os is 332,079,838 with about 148,292,180 shares in the public float. The Company has a decent balance sheet with just $1.2 million in liabilities and small but growing revenues. Many have pointed out that they like the direction that CEOS is going and it’s easy to see why; the Company has been busy behind the scenes bringing on a top-level management team and BOD appointed Dr. Shahiem Hartley as well as Renowned Biochemist Dr. Michael J. McCarthyto its Medical Advisory Board. They also appointed Corporate Executive & Scientific Innovator John Gustin as Head of Global Business Development. The Company is acquiring VetComm in a deal that could prove extremally lucrative if Vetcomm achieves anywhere near the goal of helping one million Veterans get disability compensation. CEOS does have a history of big moves making a historic run from well under a penny to highs near $0.50 in early 2021.   We will be updating on CEOS when more details emerge so make sure you are subscribed to Newsytrends.com by entering your email below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in CEOS either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.